© 2021 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2021 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
June 18, 2020
A phase 3 trial designed to evaluate eprenetapopt plus azacytidine (Vidaza) in patients with TP53-mutant positive myelodysplastic syndrome (MDS) completed full enrollment, according to Aprea Therapeutics, Inc.